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Abstract
Background: Hepatocellular carcinoma is an aggressive disease in Asia and Africa with poor prognosis partially due to lack of  
disease-specific biomarkers.
Objectives: The aim of  this study was to assess the concentrations of  different cytokines and chemokines in peripheral blood 
of  patients with hepatocellular carcinoma and identify the potential biomarkers that would help in clinical assessment.
Methods: Profiling of  14 cytokines, chemokines and growth factors was performed in peripheral blood of  78 patients and 78 
healthy controls using Bio-Plex Human 15-plex assay kit.
Results: The results showed that patients had significantly higher levels of  IL-1β (p=0.034), IL-6 (p=2.13e-06),IL-10 (p=0.013), 
IL-17A (p=0.017), IL-22 (p=0.00276), IL-25 (p=0.0005), but lower levels of  IL-4 (p=0.00341) and IL-33 (p=0.00982) in pe-
ripheral blood.
Conclusion: We identified a unique eight-peripheral blood cytokines signature for hepatocellular carcinoma detection. This 
work will serve as the basis for further studies about the clinical value of  peripheral blood cytokines in forecasting prognosis
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Introduction
Hepatocellular carcinoma (HCC) is one of  the most 
prevalent and lethal cancers in Asia and Africa with high 
mortality rate1. Although regular surveillance with alpha 
fetal protein (AFP) and ultrasound scan is recommended, 
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it is debatable if  this strategy improves survival2. AFP, the 
most widely available tumor marker, only has a sensitivity 
of  41-65% for HCC3. New biomarkers for earlier diag-
nosis of  HCC and identification of  high risk groups are 
required.
In the past two decades, several studies have investigat-
ed the relevance of  cytokines alterations in the multifac-
torial pathogenesis of  hepatocellular carcinoma4. Some 
cytokines mainly present during hepatocellular carcino-
ma development and can possibly be considered as state 
markers, such as IL-6 and transforming growth factor-β 
(TGF-β)5,6. It has been reported that high levels of  pro-in-
flammatory cytokines in hepatocellular carcinoma might 
be related to an over-activation of  Th17, such as IL-7A, 
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IL-17F and IL-227. However, variations in peripheral 
blood or plasma cytokines levels might not directly reflect 
the activity of  peripheral blood immune cells. Indeed, 
peripheral blood and plasma cytokines levels may partly 
derive from the vessel walls or from other lymphoid or 
non-lymphoid cells, such as hepatocytes or adipocytes8. 
For these reasons, studying cytokine expression level in 
peripheral blood might present a more reliable method to 
investigate the specific activity of  immune cells and their 
degree of  activation.
To ascertain whether a peripheral blood cytokine expres-
sion signature can distinguish hepatocellular carcinoma 
from cancer-free controls, we conducted peripheral blood 
cytokine expression profiling by Bio-Plex Human 15-plex 
assay kit and extensively evaluated peripheral blood cyto-
kine expression. By statistical analysis, we obtained a pro-
file of  eight peripheral blood cytokines, which can serves 
as a biomarker for hepatocellular carcinoma detection. 
The correlation between peripheral blood cytokine and 




Study design, patients and control subjects
A multi-stage, case-control study was designed to iden-
tify a peripheral blood cytokine profile as a biomark-
er for hepatocellular carcinoma. Seventy-eight pairs 
of  hepatocellular carcinoma clinical patients (average 
age:49.5±5.9; Female:69; Smoking:38; Alcohol consump-
tion:55; HbeAg(+):29) and matched non-tumor samples 
(average age: 50.8±4.8; Female:65; Smoking:40; Alcohol 
consumption:53; HbeAg(+):27) were collected at First 
Affiliated Hospital of  Guangxi Medical University from 
February 2014 and December 2016. The 78 HCC pa-
tients were staged according to TNM stage established 
by Union for International Cancer Control (UICC). All 
cases had been confirmed by two independent pathologic 
examinations. Informed consent was obtained from all 
patients or their guardians and the study was approved by 
the Research Ethics Committee of  First Affiliated Hospi-
tal of  Guangxi Medical University.
Quantification of  Cytokines, Chemokines
Fresh heparinized blood samples (4 mL) of  venous blood 
which was collected on an empty stomach early morning. 
The plasma samples (HCC patients and the correspond-
ing controls) were centrifuged at 3000rpm for 10 minutes 
and then stored at -80°C for further analysis. Subsequent-
ly, the samples were analyzed in duplicate using Bio-Plex 
Human 15-plex assay kit (Bio-Rad Laboratories, Her-
cules, CA) according to the manufacturer’s instructions. 
The complete list of  cytokines (IL-1β, IL-4, IL-6, IL-10, 
IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, 
IFN-γ, sCD40L and TNFα) was quantified in these co-
horts, and their detection limits and reproducibility were 
provided in the product manual. The Bio-Plex Protein 
Array System (Bio-Rad) was employed to distinguish the 
fifteen distinct sets of  fluorescently dyed beads. The de-
tection of  15 cytokine profiling had a high sensitivity and 
broad dynamic range (0-32,000pg/ml).
Statistical analysis
Statistical analysis was performed using the Statistical 
Analysis System software (v.9.1.3; SAS Institute, Cary, 
NC). Data is presented as the median±SD. Non-paramet-
ric Mann-Whitney U test was used to compare the differ-
ence of  peripheral blood cytokines between the cancer 
and healthy group. P<0.05 was considered statistically 
significant.
Results
Description and clinical characteristics of  the pa-
tients
We employed 78 hepatocellular carcinoma patients (diag-
nosed by two independent pathologic examinations) and 
78 healthy people to investigate the potential biomarkers 
of  hepatocellular carcinoma. The clinical characteristics 
of  the patients and healthy samples were represented in 
Table 1. There was no significant difference in the dis-
tribution of  smoking (p=0.749), alcohol consumption 
(p=0.729), age (p=0.059) and gender (p=0.357) between 
the cancer patients and healthy cases. Among 78 patients, 
there were 5 patients (6.41%) classified as stages I or II, 
56 (71.8%) classified as stages III, 17(21.8%) classified as 
stages IV, respectively (data not shown). Moreover, elevat-
ed levels of  AFP (>100ng/ml) were found in 31(39.7%) 
patients (data not shown).
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Table 1.  Characteristics of the participants 
 
Item Case (n=78) Control(n=78) χ2/t P 
Age 49.5±5.9 50.8±4.8 -1.901 0.059 
Female 69 65 0.847 0.357 
Smoking 38 40 0.103 0.749 
Alcohol 
consumption 55 53 0.120 
0.729 
  
TNM stage I-II 5     
  III 56     
  IV 17     
  
  
Cytokine profiling of  peripheral blood in hepatocel-
lular carcinoma and healthy controls
Bio-Plex Human 15-plex assay kit was used to detect the 
cytokines expression levels in peripheral blood. 15 differ-
ent cytokines in peripheral blood were assessed in both 
patient and control subjects. The data showed that there 
were 14 kinds of  cytokines which were detected in pe-
ripheral blood (IL_31 was not detected). The result re-
vealed that among the 14 kinds of  cytokines in patients 
with hepatocellular carcinoma, only eight kinds of  cyto-
kines have statistical significance (Table 2, p<0.001). 
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Table 2. Comparision of cykotines between paitents vs. healthy control 
 
Cykotines Group N Mean±S.D t/Z P 
IL_1β 
case 78 30.16±7.46 -10.508* <0.001 
control 78 12.55±4.32     
IL_4 
case 78 36.67±5.34 -10.729* <0.001 
control 78 67.26±10.93     
IL_6 
case 78 3765.71±806.91 -10.782* <0.001 
control 78 177.35±29.00     
IL_10 
case 78 60.90±10.05 -10.783* <0.001 
control 78 19.10±3.89     
IL_17A 
case 78 5.02±1.36 -11.005* <0.001 
control 78 1.08±0.22     
IL_17F 
case 78 2.64±0.40 -1.778 0.075 
control 78 2.49±0.81     
IL_21 
case 78 31.57±6.79 -0.454 0.650 
control 78 30.99±5.19     
IL_22 
case 78 5.14±1.08 9.657* <0.001 
control 78 10.45±3.02     
IL_23 
case 78 19.02±3.95 0.562 0.575 
control 78 18.62±4.83     
IL_25 
case 78 2.10±0.37 10.780* <0.001 
control 78 0.69±0.21     
IL_33 
case 78 292.52±48.80 -14.744* <0.001 
control 78 410.06±50.73     
IFN_γ 
case 78 3.07±0.57 -0.724 0.470 
control 78 3.15±0.79     
sCD40L 
case 78 1.29±0.46 -1.396 0.165 
control 78 1.39±0.44     
TNF_α 
case 78 11.62±3.29 0.585 0.559 
control 78 11.27±4.08     
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From the findings we found that patients with hepatocel-
lular carcinoma had significantly higher peripheral blood 
levels of  IL-1β (30.16±7.46 vs. 12.55±4.32, p<0.001), 
IL-6 (3765.71±806.91 vs. 177.35±29.00, p<0.001), IL-
10 (60.90±10.05 vs. 19.10±3.89, p<0.001), IL-17A 
(5.02±1.36 vs. 1.08±0.22, p<0.001), and, IL-25 (2.10±0.37 
vs. 0.69±0.21, p<0.001). However, the level of  IL-4 
(36.67±5.34 vs. 67.26±10.93, p<0.001), IL-22 (5.14±1.08 
vs. 10.45±3.02, p<0.001), and IL-33 (292.52±48.80 vs. 
410.06±50.73, p<0.001) were significant down regulated 
compared with the healthy controls (Figure 1).
 
  
Figure1. Comparaison of peripheral blood levels of IL-4,IL-1β, IL-6,  
IL-10, IL-17A, IL-22, IL-25, IL-33 in patients and healthy controls. 
ROC analysis of  eight cytokines
In order to investigate the diagnostic values of  the eighty 
cytokine for hepatocellular carcinoma we performed re-
ceiver operating characteristic (ROC) curve analysis (Ta-
ble 3). 
Table 3.  ROC characteristics of the eighty cytokines 
 
  AUC Cutoff Sensitivity Specifivcity P value 
IL_1β 0.987 20.41 83.33% 98.72% <0.001 
IL_4 0.998 47.08 97.44% 98.72% <0.001 
IL_6 1.0 233.89 100.0% 100.0% <0.001 
IL_10 1.0 28.2 100.0% 100.0% <0.001 
IL_17A 1.0 1.54 100.0% 100.0% <0.001 
IL_22 0.948 7.43 98.72% 83.33% <0.001 
IL_25 1.0 1.24 100.0% 100.0% <0.001 
IL_33 0.769 355.32 88.46% 88.46% <0.001 
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As seen, there were 5 elevated cytokines vs. 3 repressed 
cytokines among the eight cytokines detected. The ROC 
characteristic of  the five significant increased cyto-
kines were IL-1β (AUC: Area Under the Curve=0.987, 
P<0.001; Cutoff=20.41, Sensitivity=83.33%, Specifici-
ty=98.72%), IL-6 (AUC=1.0, P<0.001; Cutoff=233.89, 
Sensi t iv i ty=100.0%,Specif ic i ty=100.0%),IL-10 
(AUC=1.0, P<0.001; Cutoff=28.2, Sensitivity=100.0%, 
Specificity=100.0%), IL-17A (AUC=1.0, P<0.001; Cut-
off=1.54,Sensitivity=100.0%, Specificity=100.0%), IL-25 
(AUC=1.0, P<0.001; Cutoff=1.24, Sensitivity=100.0%, 
Specificity=100.0%). In addition, the ROC character-
istic of  the three significant decreased cytokines were 
IL-4 (AUC=0.998, P<0.001; Cutoff  =47.08, Sensitivi-
ty=97.44%, Specificity=98.72%), IL-22 (AUC=0.948, 
P<0.001;Cutoff=7.43, Sensitivity=98.72%, Specifici-
ty=83.33%), and IL-33 (AUC=0.769, P<0.001; Cut-
off=355.32, Sensitivity=88.46%, Specificity=88.46%), 
respectively (Figure 2). The AUC of  the eight were all 
greater than 0.7 which indicated that they represented a 
high diagnostic value. Furthermore, the high sensitivity 
and specificity of  the 8 cytokines demonstrated their po-
tential role for diagnosis which was consistent with the 
AUC result.
 
Figure 2. ROC analyses of peripheral blood levels of IL-4, IL-1β, IL-6, 
IL-10, IL-17A, IL-22, IL-25, IL-33 in patients and healthy controls. 
Discussion
Hepatocellular carcinoma usually has a poor progno-
sis mostly due to an advanced stage at the time of  di-
agnosis9,10. So developing early diagnostic methods at an 
earlier stage may help to improve prognosis. However, 
early diagnostic methods with accurate performance and 
high-throughout biomarkers for hepatocellular carcino-
ma are not yet available. In the quest for cancer biomark-
ers, systemic inflammations is frequently highlighted as 
a potential confounding factor, as cancer development 
and inflammation have been reported to be associated11. 
In addition, it was known that the identified peripheral 
blood immune signatures could be considered as snap-
shots of  the immunologic activity in a patient at the time 
of  sampling. Hence, these fingerprints reflect a combina-
tion of  indirect systemic effects in response to the cancer, 
as well as factors secreted by the tumor6.
On the basis of  the notion that immune-regulation is a 
particular phenomenon in hepatocellular carcinoma, we 
thus performed the Bio-plex Human cytokines assay to 
detect the peripheral blood cytokines. The result showed 
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that levels of  cytokines IL-1β, IL-6, IL-10, IL-17A, and 
IL-25 are elevated, but cytokines IL-4, IL-22 and IL-33 
were decreased in patients’ peripheral blood. Moreover, 
we employed ROC curve analysis to investigate the po-
tential values of  the eighty cytokine for hepatocellular 
carcinoma. The result revealed that the AUC of  the eight 
were all greater than 0.7 which indicated they represented 
a high diagnostic value. Furthermore, the high sensitivi-
ty and specificity of  the 8 cytokines demonstrated their 
potential role for diagnosis which was consistent with 
the AUC result. However, there were some limitations in 
the present study. We identified a unique eight-peripheral 
blood cytokines signature for hepatocellular carcinoma 
detection but the cytokines are many and this makes it 
difficult to be widely used in clinics. The prominent cyto-
kines among these eight cytokines need to be selected in 
the further studies to provide a wide use for the patho-
genesis of  HCC. As well, the effect of  staging of  HCC 
on the levels of  cytokines should be investigated in the 
further studies.
In sum, we identified a unique eight-peripheral blood cy-
tokines signature for hepatocellular carcinoma detection. 
This work will serve as the basis for further studies about 




The relationship between Th17 and disease of  hepatocel-
lular cancer from GuangXi (GuiKegong: 1230013).
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